{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:19:52Z","timestamp":1787847592361,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The aim of the sudy was to evaluate potential role of oral captopril, an angiotensin-converting enzyme (ACE) inhibitor, and in treatment of infantile hemagioma (IH) and report our preliminary results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This prospective study included 18 children with IH admitted in the department of pediatric surgery with no history of prior treatment of any type. Baseline blood pressure (BP), electrocardiogram, two-dimensional echocardiography, serum electrolytes, and renal function test (RFT) were noted. Oral captopril was started as first-line drug at a dose of 0.1 mg\/kg orally 12 h with gradually increase of dosage up to 2.0 mg\/kg 12 h over the period of 10 days with monitoring of BP, serum electrolytes, RFT, and occurrence of any side effect. If no side effects were noted and patients were stable, they were discharged and followed up until 6 months after stopping treatment. During follow-up, response to treatment was documented clinically and photographically. Development of any side effect was also noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Excellent response to captopril was noticed in nine patients over 16\u201318 months. Four patients showed good response. Oral propranolol had to be administered alternatively in one patient showing fair response during the initial 4 months but no response afterward and in four patients showing no response at all. One patient developed an allergic reaction to propranolol and was started oral corticosteroid. These five patients had near complete resolution of lesion for the next 8\u201310 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>ACE inhibitors might have a role, though slow, in the involution of IHs. Therefore, these may have the potential to emerge as an alternative treatment for IH in future after confirmation with randomized studies with propranolol.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jiaps.jiaps_112_20","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T10:21:43Z","timestamp":1626085303000},"page":"234-239","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Angiotensin-converting Enzyme Inhibitors"],"prefix":"10.4103","volume":"26","author":[{"given":"Archika","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv Narain","family":"Kureel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurmeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Shandilya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul Kumar","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Survesh Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240905","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00383-013-3283-y","article-title":"Propranolol therapy of infantile hemangiomas: Efficacy, adverse effects, and recurrence","volume":"29","author":"Xiao","year":"2013","journal-title":"Pediatr Surg Int"},{"key":"R2-5-20240905","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI117241","article-title":"Cellular markers that distinguish the phases of hemangioma during infancy and childhood","volume":"93","author":"Takahashi","year":"1994","journal-title":"J Clin Invest"},{"key":"R3-5-20240905","first-page":"401","article-title":"Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta","volume":"14","author":"Bielenberg","year":"1999","journal-title":"Int J Oncol"},{"key":"R4-5-20240905","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1073\/pnas.102185799","article-title":"Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis","volume":"99","author":"Ritter","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5-5-20240905","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1549-8719.1998.tb00068.x","article-title":"Increased apoptosis coincides with onset of involution in infantile hemangioma","volume":"5","author":"Razon","year":"1998","journal-title":"Microcirculation"},{"key":"R6-5-20240905","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/jcp.2010.081257","article-title":"Haemogenic endothelium in infantile haemangioma","volume":"63","author":"Itinteang","year":"2010","journal-title":"J Clin Pathol"},{"key":"R7-5-20240905","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.bjps.2010.08.039","article-title":"Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution","volume":"64","author":"Itinteang","year":"2011","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R8-5-20240905","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bjps.2015.10.020","article-title":"Serum levels of renin, angiotensin-converting enzyme and angiotensin II in patients treated by surgical excision, propranolol and captopril for problematic proliferating infantile haemangioma","volume":"69","author":"Sulzberger","year":"2016","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R9-5-20240905","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2133.2012.11016.x","article-title":"Treatment of infantile haemangioma with captopril","volume":"167","author":"Tan","year":"2012","journal-title":"Br J Dermatol"},{"key":"R10-5-20240905","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2015.09.061","article-title":"Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial","volume":"74","author":"Zaher","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R11-5-20240905","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1440-0960.2012.00901.x","article-title":"Effect of captopril on infantile haemangiomas: A retrospective case series","volume":"53","author":"Christou","year":"2012","journal-title":"Australas J Dermatol"},{"key":"R13-5-20240905","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"key":"R14-5-20240905","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/pde.12089","article-title":"Propranolol and infantile hemangiomas four years later: A systematic review","volume":"30","author":"Marqueling","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"R15-5-20240905","doi-asserted-by":"crossref","first-page":"e20160355","DOI":"10.1542\/peds.2016-0355","article-title":"Topical timolol maleate treatment of infantile hemangiomas","volume":"138","author":"P\u00fcttgen","year":"2016","journal-title":"Pediatrics"},{"key":"R16-5-20240905","doi-asserted-by":"crossref","first-page":"e1589","DOI":"10.1542\/peds.2010-0077","article-title":"Hyperkalemia complicating propranolol treatment of an infantile hemangioma","volume":"126","author":"Pavlakovic","year":"2010","journal-title":"Pediatrics"},{"key":"R17-5-20240905","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1525-1470.2009.01081.x","article-title":"Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol","volume":"27","author":"Bonifazi","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"R18-5-20240905","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/archdermatol.2010.158","article-title":"Hypoglycaemia in a child taking propranolol for the treatment of infantile hemangioma","volume":"146","author":"Holland","year":"2010","journal-title":"Arch Dermatol"},{"key":"R19-5-20240905","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/adc.63.4.360","article-title":"Captopril in heart failure secondary to a left to right shunt","volume":"63","author":"Scammel","year":"1988","journal-title":"Arch Dis Child"}],"container-title":["Journal of Indian Association of Pediatric Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jiaps.JIAPS_112_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:23:15Z","timestamp":1787844195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jiaps.JIAPS_112_20"}},"subtitle":["Can it be a Potential Treatment of Infantile Hemangioma"],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jiaps.jiaps_112_20","relation":{},"ISSN":["0971-9261"],"issn-type":[{"value":"0971-9261","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}